uniQure falls after FDA commissioner's comments on rare disease therapy
Source: SeekingAlpha
2026-02-26 10:20:14 ET
More on uniQure
- uniQure: Now What?
- uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump
- uniQure gains as FDA sets up meeting on gene therapy
- uniQure stock falls after FDA's notes on pre application of AMT-130
- Seeking Alpha’s Quant Rating on uniQure
Read the full article on Seeking Alpha
For further details see:
uniQure falls after FDA commissioner’s comments on rare disease therapy
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
